Skip navigation

Your Window into Emerging FDA and CMS Regulatory Policies Affecting Life Sciences

December 3-4, 2019
  • Arlington, VA

CBI’s FDA/CMS Summit 2019 draws the highest leadership at the FDA and CMS and delivers best available information on FDA and CMS priorities, policy changes, evidence-based practice, federal review processes on various areas of biopharma like CDER, CBER, CDRH and the most cutting-edge advances in healthcare and technology. This event is geared to the information needs of C-Suite biopharmaceutical executives, Directors/VPs of Regulatory/Government Affairs, FDA regulators, consultants, law firms, PhRMA and big pharmaceutical companies.

Featuring Acting FDA Commissioner,
Norman Sharpless

Norman Sharpless
Acting Commissioner
U.S. Food and Drug Administration (FDA)

GARNER THE LATEST REGULATORY UPDATES AND PRIORITIES AND DISCUSS:

  • Examine the strategic plans and priorities for CDER and
    the Office of New Drugs for 2019 and the year ahead
  • Understand the evolving role of RWE and PROs in
    regulatory decision-making and drug development
  • Explore shifts in the regulatory landscape for cell and
    gene therapies and next steps in removing barriers to
    access and reimbursement challenges
  • Review the current state of streamlining the rare disease
    drug review pathway
  • Consider the impact of the drug pricing debate on
    drug development pipeline decision-making
  • Analyze how to further advance the science of patient input
    and the impact on regulatory decision-making and
    reimbursement models
  • Assess evolving value-based payment models to address
    reimbursement challenges for rare disease drugs and
    advanced therapeutics
  • Identify next steps to advance biosimilars adoption in the U.S.

FDA/CMS Summit 2019

Your Window into Emerging FDA and CMS Regulatory Policies Affecting Life Sciences

CBI’s FDA/CMS Summit 2019 draws the highest leadership at the FDA and CMS and delivers best available information on FDA and CMS priorities, policy changes, evidence-based practice, federal review processes on various areas of biopharma like CDER, CBER, CDRH and the most cutting-edge advances in healthcare and technology. This event is geared to the information needs of C-Suite biopharmaceutical executives, Directors/VPs of Regulatory/Government Affairs, FDA regulators, consultants, law firms, PhRMA and big pharmaceutical companies.

Featuring Acting FDA Commissioner,
Norman Sharpless

Norman Sharpless
Acting Commissioner
U.S. Food and Drug Administration (FDA)

GARNER THE LATEST REGULATORY UPDATES AND PRIORITIES AND DISCUSS:

  • Examine the strategic plans and priorities for CDER and
    the Office of New Drugs for 2019 and the year ahead
  • Understand the evolving role of RWE and PROs in
    regulatory decision-making and drug development
  • Explore shifts in the regulatory landscape for cell and
    gene therapies and next steps in removing barriers to
    access and reimbursement challenges
  • Review the current state of streamlining the rare disease
    drug review pathway
  • Consider the impact of the drug pricing debate on
    drug development pipeline decision-making
  • Analyze how to further advance the science of patient input
    and the impact on regulatory decision-making and
    reimbursement models
  • Assess evolving value-based payment models to address
    reimbursement challenges for rare disease drugs and
    advanced therapeutics
  • Identify next steps to advance biosimilars adoption in the U.S.